- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
August 2nd, 2007
Domestic anti-cancer drug major Dabur Pharma is finalising plans to enter Japan and China. The company has started the groundwork of filing drug applications and is scouting for potential pharma acquisitions in both the countries.
Dabur Pharma also plans to expand the range of products developed on its nanotechnology drug delivery system, christened ‘Nanoxel'. At the moment, it sells the popular anti-cancer drug ‘Paclitaxel' on this platform. "We also want to export this portfolio of drugs in US, Europe and South-east Asian markets," said Mr Vij.
|Related News Press|
Particle Works launches range of high quality magnetic nanoparticles August 31st, 2016
Designing ultrasound tools with Lego-like proteins August 29th, 2016
FEI Celebrates Shipment of 1,000th Helios DualBeam System: FEI’s Helios Family has lead the DualBeam technology race and is widely used across the semiconductor, materials science, life sciences and oil & gas industries August 31st, 2016
Diamonds and quantum information processing on the nano scale August 31st, 2016
Keysight Technologies Begins Trading as Independent Company November 3rd, 2014